



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/615009/2010

European Medicines Agency decision

P/208/2010

of 29 October 2010

on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Fluad and associated names), (EMEA-000149-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/208/2010

of 29 October 2010

on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Fluad and associated names), (EMA-000149-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/40/2009 issued on 23 March 2009,

Having regard to the application submitted by Novartis Vaccines and Diagnostics S.r.l. on 28 June 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2/Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Fluad and associated names), suspension for injection in pre-filled syringe, intramuscular use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina, 1, 53100 Siena, Italy.

Done at London, 29 October 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/538035/2010

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000149-PIP01-07-M02

Scope of the application

Active substance(s):

Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1/Influenza virus
surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2/Influenza virus surface
antigens (haemagglutinin and neuraminidase) of strain B

Invented name:

Fluad and associated names

Condition(s):

Prevention of influenza

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Suspension for injection in pre-filled syringe

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Novartis Vaccines and Diagnostics S.r.l.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Vaccines and Diagnostics S.r.l. submitted to the European Medicines Agency on 28 June 2010 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/40/2009 issued on 23 March 2009.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 15 July 2010.

Scope of the modification

Some measures and/or timelines of the agreed paediatric investigation plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 10 September 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan.

1. Waiver

Condition: Prevention of Influenza

The waiver applies to:

- Children from birth to less than 2 months of age
- for Flud and associated names, suspension for injection in pre-filled syringe, intramuscular use
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric Investigation Plan

2.1. Condition: Influenza

2.1.1. Indication(s) targeted by the PIP

Prevention of influenza

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Suspension for injection in pre-filled syringe, intramuscular use

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Development of suspension for injection, 0.25 mL pre-filled syringe.
Non-clinical		Not applicable.
Clinical	5	Observer-blind, active-controlled (Vaxigrip) safety and immunogenicity study of revaccination with a third Flud dose, administered approximately 1 year apart, in children from 16 months to less than 4 years of age. Observer-blind, active- and placebo-controlled (Agrippal S1/Influsplit SSW and Menjugate/Encepur Children) three-arm safety, immunogenicity and efficacy study of two doses of Flud vaccine in children from 6 months to less than 6 years of age. Observer-blind, active-controlled (Fluzone) safety and immunogenicity study of two doses of Flud vaccine in children from 6 months to less than 5 years of age. Observer-blind, active-controlled (trivalent inactivated subunit vaccine) safety and immunogenicity study of a single dose of Flud vaccine in

		children from 6 to less than 18 years of age, healthy and at increased risk. Observer-blind, active-controlled (trivalent inactivated subunit vaccine) safety and immunogenicity study of one or two doses of Fluad vaccine in children from 2 to less than 6 months of age.
--	--	--

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues and/or efficacy in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2016
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Prevention of influenza

Authorised indications:

- Active immunisation against influenza in the elderly, especially from those with an increased risk of associated complications.

Invented name	Strength	Pharmaceutical form	Route of administration
Fluad	15 µg HA for each strain	Suspension for injection in pre-filled syringe	Intramuscular use